JP2007518815A - 乳癌および原発性胆汁性肝硬変に関与するｍｍｔｖ様ウイルスを阻害するためのアデホビルまたはテノホビルの使用 - Google Patents

乳癌および原発性胆汁性肝硬変に関与するｍｍｔｖ様ウイルスを阻害するためのアデホビルまたはテノホビルの使用 Download PDF

Info

Publication number
JP2007518815A
JP2007518815A JP2006551327A JP2006551327A JP2007518815A JP 2007518815 A JP2007518815 A JP 2007518815A JP 2006551327 A JP2006551327 A JP 2006551327A JP 2006551327 A JP2006551327 A JP 2006551327A JP 2007518815 A JP2007518815 A JP 2007518815A
Authority
JP
Japan
Prior art keywords
adefovir
tenofovir
biliary cirrhosis
primary biliary
mmtv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006551327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007518815A5 (https=
Inventor
トーマス チフラー，
ジャネット エル． ダグラス，
クレイグ エス． ギッブス，
Original Assignee
ギリアード サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ， インコーポレイテッド filed Critical ギリアード サイエンシーズ， インコーポレイテッド
Publication of JP2007518815A publication Critical patent/JP2007518815A/ja
Publication of JP2007518815A5 publication Critical patent/JP2007518815A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2006551327A 2004-01-21 2005-01-21 乳癌および原発性胆汁性肝硬変に関与するｍｍｔｖ様ウイルスを阻害するためのアデホビルまたはテノホビルの使用 Pending JP2007518815A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53806604P 2004-01-21 2004-01-21
PCT/US2005/002043 WO2005072748A1 (en) 2004-01-21 2005-01-21 Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis

Publications (2)

Publication Number Publication Date
JP2007518815A true JP2007518815A (ja) 2007-07-12
JP2007518815A5 JP2007518815A5 (https=) 2008-03-13

Family

ID=34825960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006551327A Pending JP2007518815A (ja) 2004-01-21 2005-01-21 乳癌および原発性胆汁性肝硬変に関与するｍｍｔｖ様ウイルスを阻害するためのアデホビルまたはテノホビルの使用

Country Status (10)

Country Link
US (2) US20070281911A1 (https=)
EP (1) EP1732569B1 (https=)
JP (1) JP2007518815A (https=)
AT (1) ATE445404T1 (https=)
AU (1) AU2005209256B2 (https=)
CA (1) CA2553455A1 (https=)
DE (1) DE602005017131D1 (https=)
ES (1) ES2334149T3 (https=)
NZ (1) NZ548532A (https=)
WO (1) WO2005072748A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506837A (ja) * 2009-10-05 2013-02-28 アンバージェン， インコーポレイテッド 自己抗原を使用する原発性胆汁性肝硬変（ｐｂｃ）を診断するための方法
JP2018522836A (ja) * 2015-06-01 2018-08-16 エクイガーミナル エスエー 抗ウイルス組成物
KR20200026156A (ko) * 2018-08-30 2020-03-10 가톨릭대학교 산학협력단 테노포비르 디소프록실 푸마르산을 유효성분으로 함유하는, 간섬유증 예방 또는 치료용 약학적 조성물
JPWO2020171225A1 (ja) * 2019-02-22 2021-12-16 一素 村田 ｍＴＯＲ阻害剤

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114064A2 (en) * 2005-04-25 2006-11-02 Institute Of Organic Chemistry And Biochemistry Ofthe Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
RU2301088C2 (ru) * 2005-09-01 2007-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения рецидива рака молочной железы
EP2020996B1 (en) 2006-05-16 2011-11-23 Gilead Sciences, Inc. Method and compositions for treating hematological malignancies
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
EP4556010A3 (en) 2011-11-30 2025-07-23 Emory University Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
US10301624B2 (en) 2014-06-25 2019-05-28 The General Hospital Corporation Targeting human satellite II (HSATII)
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
JP6804790B1 (ja) 2017-12-07 2020-12-23 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
EP3993873A4 (en) * 2019-07-02 2023-09-20 Virago Vax Inc. SUPPRESSION OF BREAST TUMORS
US12029783B2 (en) 2019-07-02 2024-07-09 Virago Vax Inc. Mammary tumor virus vaccine
US12016844B2 (en) 2019-07-02 2024-06-25 Virago Vax Inc. Mammary tumor virus suppression
TW202400134A (zh) 2022-03-15 2024-01-01 美商羅米醫療公司 用於治療疾病之化合物及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512023A (ja) * 1999-06-01 2003-04-02 アルトン オケスナー メディカル ファウンデーション 原発性胆汁性肝硬変および自己免疫障害に関連する新規レトロウイルスの同定

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369848C (en) * 1999-06-30 2011-09-20 Robert F. Garry Human endogenous retrovirus in breast cancer
CZ304734B6 (cs) * 2000-07-21 2014-09-10 Gilead Sciences, Inc. Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu
NZ536328A (en) * 2002-05-13 2007-11-30 Metabasis Therapeutics Inc Novel phosphonic acid based prodrugs of PMEA and its analogues

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512023A (ja) * 1999-06-01 2003-04-02 アルトン オケスナー メディカル ファウンデーション 原発性胆汁性肝硬変および自己免疫障害に関連する新規レトロウイルスの同定

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506837A (ja) * 2009-10-05 2013-02-28 アンバージェン， インコーポレイテッド 自己抗原を使用する原発性胆汁性肝硬変（ｐｂｃ）を診断するための方法
JP2018522836A (ja) * 2015-06-01 2018-08-16 エクイガーミナル エスエー 抗ウイルス組成物
KR20200026156A (ko) * 2018-08-30 2020-03-10 가톨릭대학교 산학협력단 테노포비르 디소프록실 푸마르산을 유효성분으로 함유하는, 간섬유증 예방 또는 치료용 약학적 조성물
KR102196711B1 (ko) * 2018-08-30 2020-12-30 가톨릭대학교 산학협력단 테노포비르 디소프록실 푸마르산을 유효성분으로 함유하는, 간섬유증 예방 또는 치료용 약학적 조성물
JPWO2020171225A1 (ja) * 2019-02-22 2021-12-16 一素 村田 ｍＴＯＲ阻害剤
JP7663236B2 (ja) 2019-02-22 2025-04-16 一素 村田 ｍＴＯＲ阻害剤

Also Published As

Publication number Publication date
US20070281911A1 (en) 2007-12-06
EP1732569B1 (en) 2009-10-14
EP1732569A1 (en) 2006-12-20
DE602005017131D1 (de) 2009-11-26
HK1099228A1 (en) 2007-08-10
WO2005072748A1 (en) 2005-08-11
CA2553455A1 (en) 2005-08-11
AU2005209256A1 (en) 2005-08-11
ES2334149T3 (es) 2010-03-05
AU2005209256B2 (en) 2010-11-18
NZ548532A (en) 2009-09-25
ATE445404T1 (de) 2009-10-15
US20050239753A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
JP2007518815A (ja) 乳癌および原発性胆汁性肝硬変に関与するｍｍｔｖ様ウイルスを阻害するためのアデホビルまたはテノホビルの使用
JP6616387B2 (ja) ホルボールエステルを含む組成物及びその使用法
TWI905508B (zh) 用於治療病毒感染之方法
US20120321637A1 (en) Combination cancer therapy with herv inhibition
US20240043466A1 (en) Solid forms of a nucleoside analogue and uses thereof
ES2356986T3 (es) Agentes antitumorales.
JP2020203947A (ja) Ｎｓ５ａ、ｎｓ５ｂまたはｎｓ３阻害剤を使用する、ｂ型肝炎ウイルス感染症を処置するための方法
US20230158103A1 (en) Pld for use in combination in the treatment of coronavirus
ES2280259T3 (es) Complejos de galio de 3-hidroxi-4-pironas para tratar infecciones por procariotas intracelulares, virus de adn y retrovirus.
WO2007149382A2 (en) Therapeutic compositions and methods useful in treating hepatitis
ES2978336T3 (es) Combinación de un inhibidor de Mcl-1 y midostaurina, usos y composiciones farmacéuticas de la misma
Morris-Natschke et al. Phospholipid analogs against HIV-1 infection and disease
US20070202079A1 (en) Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
CN106999596A (zh) 菜蓟滴定提取物及其用途
WO2007149381A2 (en) Compositions comprising a ptp-ase inhibitor and use thereof in treating cancer
Sternfeld et al. Increased red cell corpuscular volume and hepatic mitochondrial function in NRTI-treated HIV infected patients
HK1099228B (en) Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
WO2016183276A1 (en) Immune modulation methods to reactivate hiv-1 reservoir
CN113143924A (zh) 硫代咪唑烷酮药物在治疗covid-19疾病中的用途
EP4259100A1 (en) Materials and methods for treating viral and other medicinal conditions
EP1038529A2 (en) Agent for increasing chemokine production
JPH11315019A (ja) 腎透析に伴うそう痒の治療剤
CN113365630A (zh) 用于鳞状细胞癌的疗法
JP2011519925A (ja) Ｌａｐｃ−４前立腺癌細胞のｉｇｆ−１受容体およびアンドロゲン依存性増殖に対するノルジヒドログアイアレチン酸（ｎｄｇａ）の阻害効果
WO2025137446A1 (en) Solid forms of a nucleoside analogue and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110726

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110802

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111115